Abstract
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
Highlights
New antimalarials are needed to address the threat of emerging artemisinin resistance
Systemic exposure in terms of AUCinf increased in a dose-proportional manner over the dose range of 1300 mg
KAE609 is a new antimalarial with potential to address artemisinin resistance, and demonstrates a half-life of around 24 hours and dose-proportional increase in systemic exposure
Summary
A first-in-human randomized, double-blind, placebo-controlled, single- and multipleascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers. Joel Leong1*, Ruobing Li2, Jay Prakash Jain, Gilbert Lefèvre, Baldur Magnusson, Thierry Diagana, Peter Pertel. From Challanges in malaria research: Core science and innovation Oxford, UK. From Challanges in malaria research: Core science and innovation Oxford, UK. 22-24 September 2014
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
